Holen Sie sich die Stockscreener-App
3.96
0.25%
-0.01
Handel nachbörslich:
3.95
-0.010
-0.25%
Schlusskurs vom Vortag:
$3.97
Offen:
$3.89
24-Stunden-Volumen:
467.52K
Relative Volume:
0.59
Marktkapitalisierung:
$503.10M
Einnahmen:
$81.36M
Nettoeinkommen (Verlust:
$-142.62M
KGV:
-3.2975
EPS:
-1.2009
Netto-Cashflow:
$-146.97M
1W Leistung:
-1.98%
1M Leistung:
-4.12%
6M Leistung:
+8.49%
1J Leistung:
+150.63%
1-Tages-Spanne:
$3.89
$4.05
1-Wochen-Bereich:
$3.84
$4.12
52-Wochen-Spanne:
$1.05
$4.98
Adc Therapeutics Sa Stock (ADCT) Company Profile
Firmenname
Adc Therapeutics Sa
Sektor
Branche
Telefon
41 21 653 02 00
Adresse
BIOPOLE, EPALINGES
Compare ADCT vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ADCT
Adc Therapeutics Sa
|
3.96 | 504.37M | 81.36M | -142.62M | -146.97M | -1.2009 |
VRTX
Vertex Pharmaceuticals Inc
|
453.74 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
756.73 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
692.83 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.60 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Adc Therapeutics Sa Stock (ADCT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-08 | Eingeleitet | Stephens | Overweight |
| 2024-05-30 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-03-28 | Eingeleitet | Guggenheim | Buy |
| 2023-08-10 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2023-04-24 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-12-06 | Eingeleitet | CapitalOne | Overweight |
| 2022-11-09 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-09-21 | Eingeleitet | JP Morgan | Overweight |
| 2022-09-09 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-11-09 | Eingeleitet | Wolfe Research | Outperform |
| 2021-08-17 | Fortgesetzt | Jefferies | Buy |
| 2021-08-09 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-06-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-12-03 | Eingeleitet | Stifel | Hold |
| 2020-10-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-06-09 | Eingeleitet | BofA/Merrill | Buy |
| 2020-06-09 | Eingeleitet | Cowen | Outperform |
Alle ansehen
Adc Therapeutics Sa Aktie (ADCT) Neueste Nachrichten
ADC Therapeutics Eyes ZYNLONTA Expansion as LOTIS-5 Data Nears at H.C. Wainwright Chat - Yahoo Finance
ADC Therapeutics (NYSE:ADCT) Shares Gap Up on Analyst Upgrade - Defense World
ADC Therapeutics (NYSE:ADCT) Price Target Raised to $8.00 - MarketBeat
ADC Therapeutics (ADCT) Reports 2025 Revenue of $73.6M With Cash Runway Into 2028 - Yahoo Finance
US Stocks Recap: Can ADC Therapeutics SA disrupt its industryRate Hike & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Heights Capital Management Inc. Has $1.31 Million Position in ADC Therapeutics SA $ADCT - MarketBeat
Growth Recap: Will ADC Therapeutics SA benefit from rate cuts2026 Dividend Review & Technical Entry and Exit Tips - baoquankhu1.vn
Fed Watch: Is ADC Therapeutics SA stock showing strong momentumMarket Rally & AI Enhanced Market Trend Forecasts - baoquankhu1.vn
[EFFECT] ADC Therapeutics SA S... | ADCT SEC FilingForm EFFECT - Stock Titan
ADC Therapeutics (ADCT) registers 9.83M shares issuable on HCR warrants - Stock Titan
ADC Therapeutics signals ZYNLONTA peak revenue potential of $600M–$1B in U.S. with expanded clinical milestones - MSN
ADC Therapeutics SA $ADCT Stock Holdings Reduced by Prosight Management LP - MarketBeat
Is ADC Therapeutics (ADCT) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Wall Street Recap: Can ADC Therapeutics SA expand its profit margins2026 Setups & Growth Focused Investment Plans - baoquankhu1.vn
ADC Therapeutics (NYSE:ADCT) Shares Down 9.2%Should You Sell? - MarketBeat
ADC Therapeutics SA Hits New 52-Week High of $4.95, Up 31.87% - Markets Mojo
ADC Therapeutics SA: 2025 Annual Report Highlights – ZYNLONTA Pipeline, Global Partnerships, and Antibody-Drug Conjugate Innovation - Minichart
ADC Therapeutics SA (ADCT) Reports Wider Loss Q4 EPS Estimates by 85.1% - AlphaStreet
ADC Therapeutics SA 2025 Q4ResultsEarnings Call Presentation (NYSE:ADCT) 2026-03-11 - Seeking Alpha
Aug Shorts: Can ADC Therapeutics SA continue delivering strong returns2026 PreEarnings & Weekly Stock Breakout Alerts - baoquankhu1.vn
ADC Therapeutics reports Q4 revenue of $22.3 million By Investing.com - Investing.com Canada
ADC Therapeutics (NYSE:ADCT) Reaches New 12-Month High Following Strong Earnings - MarketBeat
According to the latest filings submitted to the U.S. Securities and Exchange Commission (SEC), some shareholders of the biopharmaceutical company ADC Therapeutics SA may gradually sell their holdings of the company's common stock over a period of tim - Bitget
ADC Therapeutics 2025 10-K: $81.4M Revenue, $(1.12) EPS - TradingView
[ARS] ADC Therapeutics SA SEC Filing - Stock Titan
ADC Therapeutics SA (ADCT) Q4 2025 Earnings Call Highlights: Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
ADC Therapeutics Q4 2025 Earnings Call Insights - Intellectia AI
ADC Therapeutics Q4 2025 Earnings Call Transcript - MarketBeat
ADC Therapeutics SA Files 8-K Report Detailing Company Information and Common Shares Listing on NYSE - Minichart
ADC Therapeutics Q4 Earnings Call Highlights - MarketBeat
ADC Therapeutics (NYSE:ADCT) Shares Gap Up After Strong Earnings - MarketBeat
ADC Therapeutics Narrows Losses, Supported By Higher Product Revenue And Ongoing Restructuring - RTTNews
ADC Therapeutics outlines $600M–$1B peak revenue target for ZYNLONTA as LOTIS-5 and LOTIS-7 advance - MSN
ADC Therapeutics reports Q4 revenue of $22.3 million - Investing.com
ADC Therapeutics SA reports results for the quarter ended December 31Earnings Summary - TradingView
ADC Therapeutics SA Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Finan - GuruFocus
ADC Therapeutics (NYSE:ADCT) Announces Earnings Results - MarketBeat
ADC Therapeutics SA (ADCT) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
ADCT: 4Q 2025 revenue up 36% YoY, net loss down 79%, and ZYNLONTA pipeline advances - TradingView
ADC Therapeutics Q4 Revenue $23.06M Beats Expectations - Intellectia AI
ADC Therapeutics reports Q4 revenue $22.3M, FY2025 revenue $73.6M; cash $261.3M - TradingView
ADC Therapeutics (NYSE: ADCT) cuts 2025 loss and extends cash runway to 2028 - Stock Titan
ADC THERAPEUTICS SA -REDH ($ADCT) Releases Q4 2025 Earnings - Quiver Quantitative
ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update - PR Newswire
Earnings Scheduled For March 10, 2026 - Benzinga
Earnings Risk: Can ADC Therapeutics SA continue delivering strong returns2026 Selloffs & Scalable Portfolio Growth Ideas - baoquankhu1.vn
ADC Therapeutics SA (ADCT) Posts Fourth Quarter Loss, Surpasses Revenue Projections - Bitget
What to Expect from ADC Therapeutics's Earnings - Benzinga
ADC Therapeutics SA (ADCT) Q4 2025: Everything You Need to Know Ahead of Earnings - GuruFocus
Why ADC Therapeutics SA stock remains a top recommendationJuly 2025 Retail & Low Drawdown Momentum Ideas - Naître et grandir
Finanzdaten der Adc Therapeutics Sa-Aktie (ADCT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.04%
0.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):